Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

3.2K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Comprehensive mapping of identical sequences across human proteins emphasizes the widespread issue of shared epitopes in self-antigens.

NAR genomics and bioinformatics·2026
Same author

Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort.

Breast (Edinburgh, Scotland)·2026
Same author

Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Dihydropyrimidine Dehydrogenase-Guided Dosing of 5-Fluorouracil: Prioritizing Precision Over Dose Reduction.

JCO precision oncology·2025
Same author

PROTACs and Glues: Striking Perspectives for Engineering Cancer Therapy À La Carte.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

De-Escalating Anticancer Treatment: Watch Your Step.

Cancers·2025

相关实验视频

Updated: Jan 9, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.2K

重新思考EPO:瘤学的范式转变?

Jean-Marc Ferrero1, Baharia Mograbi2, Rym Bouriga3

  • 1Department of Medical Oncology, Antoine Lacassagne Center, University Côte d'Azur, 33 Avenue de Valombrose, 06189 Nice, France.

Cancers
|December 11, 2025
PubMed
概括
此摘要是机器生成的。

红素 (EPO) 治疗改善癌症贫血,但也可能促进瘤生长. 重新评估欧洲专利局

关键词:
贫血 贫血 是一种疾病.癌症治疗 治疗 治疗 癌症红色素素是一种人体蛋白质.免疫疗法 免疫疗法巨细胞是一个巨细胞.

更多相关视频

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K

相关实验视频

Last Updated: Jan 9, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.2K
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K

科学领域:

  • 在瘤学瘤学.
  • 血液学 血液学 血液学
  • 内分泌学 在内分泌学.

背景情况:

  • 红色素 (EPO) 是一种由脏产生的激素,可刺激红细胞的产生.
  • 再组合EPO有效治疗与癌症相关的贫血,提高患者的生活质量.
  • 新出现的证据表明,EPO在瘤生物学中具有非血液形成作用.

研究的目的:

  • 探索红素 (EPO) 在癌症治疗中的双重作用.
  • 重新评估EPO在医疗瘤学中的风险/益处概况.
  • 突出EPO对瘤进展和免疫抑制的潜在贡献.

主要方法:

  • 对EPO在瘤学中的功能进行当前科学文献的审查.
  • 对调查瘤细胞EPO受体表达的研究进行分析.
  • 对EPO对瘤微环境的影响研究的审查.

主要成果:

  • 在治疗与癌症相关的贫血中,EPO已确定的益处与潜在的风险形成对比.
  • 有证据表明,EPO受体可能会在瘤细胞上表达,这引起了人们的担忧.
  • 最近的发现表明,EPO可能会在瘤微环境中诱导免疫抑制机制.

结论:

  • 在瘤学中,EPO呈现出一种悖论:一种具有潜在瘤风险的治疗剂.
  • 需要进一步客观地重新评估EPO复杂的作用.
  • 建议在关于EPO在癌症患者使用的临床决策中更加谨慎.